Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ironwood Pharmaceuticals, Inc. (IRWD)

11.91   0 (0%) 12-07 16:00
Open: 11.9 Pre. Close: 11.91
High: 12.105 Low: 11.86
Volume: 1,337,494 Market Cap: 1,827(M)

Technical analysis

as of: 2022-12-07 4:23:18 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.4     One year: 16.82
Support: Support1: 11.43    Support2: 10.88
Resistance: Resistance1: 12.32    Resistance2: 14.4
Pivot: 11.75
Moving Average: MA(5): 12     MA(20): 11.68
MA(100): 11.15     MA(250): 11.44
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 65.4     %D(3): 74.4
RSI: RSI(14): 58.7
52-week: High: 12.94  Low: 9.72
Average Vol(K): 3-Month: 1,986 (K)  10-Days: 1,285 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IRWD ] has closed below upper band by 35.6%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.12 - 12.19 12.19 - 12.25
Low: 11.68 - 11.77 11.77 - 11.85
Close: 11.78 - 11.91 11.91 - 12.03

Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Headline News

Tue, 29 Nov 2022
Insiders at Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) sold US$1.8m worth of stock, possibly indicating weakness in the future - Simply Wall St

Tue, 22 Nov 2022
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference - Marketscreener.com

Mon, 21 Nov 2022
IBD Rating Upgrades: Ironwood Pharm Cl A Flashes Improved Technical Strength - Investor's Business Daily

Thu, 03 Nov 2022
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 25 Oct 2022
They’re Often in the Shadows of Elections. But Where Do Water District Candidates Stand on the Issues? - Voice of OC

Wed, 05 Oct 2022
Ironwood Pharmaceuticals Stock: Rinse, Wash And Repeat (NASDAQ:IRWD) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 153 (M)
Shares Float 134 (M)
% Held by Insiders 1.6 (%)
% Held by Institutions 115.6 (%)
Shares Short 17,150 (K)
Shares Short P.Month 17,390 (K)

Stock Financials

EPS 0.92
EPS Est Next Qtl -0.24
EPS Est This Year -1.12
EPS Est Next Year -0.58
Book Value (p.s.) 3.85
Profit Margin (%) 39.8
Operating Margin (%) 56.7
Return on Assets (ttm) 14
Return on Equity (ttm) 28.6
Qtrly Rev. Growth 4.6
Gross Profit (p.s.) 2.23
Sales Per Share 2.74
EBITDA (p.s.) 1.56
Qtrly Earnings Growth -18
Operating Cash Flow 259 (M)
Levered Free Cash Flow 160 (M)

Stock Valuations

PE Ratio 12.94
PEG Ratio 0.1
Price to Book value 3.08
Price to Sales 4.34
Price to Cash Flow 7.04

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.